De teelt van houtig kleinfruit

De teelt en rassen van rode (ook onder glas) en zwarte bessen, kruisbes, framboos en bramen wordt uitgebreid beschreven. Daarnaast is er een hoofdstuk met een korte beschrijving van de teelt van blauwe bes, rozebottel, Loganbes, Taybes, witte bes, Japanse wijnbes, Boysenbes, Jostabes en Worcesterbes. Areaalcijfers van 1960 tot 1982. Productie, in- en uitvoer van 1974-1982. Prijzen van 1974 en 1975. De bestemming voor verwerking van 1965 tot 197

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None

Impact of COVID-19 infection on the outcome of patients with ischemic stroke

BACKGROUND AND PURPOSE: We evaluated whether stroke severity, functional outcome, and mortality are different in patients with ischemic stroke with or without coronavirus disease 2019 (COVID-19) infection. METHODS: A prospective, observational, multicentre cohort study in Catalonia, Spain. Recruitment was consecutive from mid-March to mid-May 2020. Patients had an acute ischemic stroke within 48 hours and a previous modified Rankin Scale (mRS) score of 0 to 3. We collected demographic data, vascular risk factors, prior mRS score, National Institutes of Health Stroke Scale score, rate of reperfusion therapies, logistics, and metrics. Primary end point was functional outcome at 3 months. Favourable outcome was defined depending on the previous mRS score. Secondary outcome was mortality at 3 months. We performed mRS shift and multivariable analyses. RESULTS: We evaluated 701 patients (mean age 72.3±13.3 years, 60.5% men) and 91 (13%) had COVID-19 infection. Median baseline National Institutes of Health Stroke Scale score was higher in patients with COVID-19 compared with patients without COVID-19 (8 [3–18] versus 6 [2–14], P=0.049). Proportion of patients with a favourable functional outcome was 33.7% in the COVID-19 and 47% in the non-COVID-19 group. However, after a multivariable logistic regression analysis, COVID-19 infection did not increase the probability of unfavourable functional outcome. Mortality rate was 39.3% among patients with COVID-19 and 16.1% in the non-COVID-19 group. In the multivariable logistic regression analysis, COVID-19 infection was a risk factor for mortality (hazard ratio, 3.14 [95% CI, 2.10–4.71]; P<0.001). CONCLUSIONS: Patients with ischemic stroke and COVID-19 infection have more severe strokes and a higher mortality than patients with stroke without COVID-19 infection. However, functional outcome is comparable in both groups

De teelt van houtig kleinfruit

De teelt en rassen van rode (ook onder glas) en zwarte bessen, kruisbes, framboos en bramen wordt uitgebreid beschreven. Daarnaast is er een hoofdstuk met een korte beschrijving van de teelt van blauwe bes, rozebottel, Loganbes, Taybes, witte bes, Japanse wijnbes, Boysenbes, Jostabes en Worcesterbes. Areaalcijfers van 1960 tot 1982. Productie, in- en uitvoer van 1974-1982. Prijzen van 1974 en 1975. De bestemming voor verwerking van 1965 tot 197

The Effect of Processing on Some Microstructural Characteristics of Fat Spreads

The processing and the composition of fat spreads determine to a large extent the final product properties such as hardness, spreadability, mouthfeel, emulsion stability and salt release. In establishing the relation between composition, processing and final product properties, microstructural studies play an important role. In this context the influence of some process parameters in the production of shortenings and 80% fat spreads on microstructure and product properties has been investigated. Shear, cooling regime and crystallization conditions influence both the emulsion structure and the fat crystalline matrix. In general, working leads to softer products with a more granular crystalline fat matrix, whereas the water droplet size distribution is influenced in a complicated manner by the conditions of shear. This type of work indicates ways to control and manipulate the microstructure and product properties of fat spreads

Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells

10.1186/s13046-015-0157-2Journal of Experimental and Clinical Cancer Research3413

Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents

Molecular tumour pathology - and tumour geneticsMTG

Grafting of venous leg ulcers. An intraindividual comparison between cultured skin equivalents and full-thickness skin punch grafts

Skin equivalents that consisted of a noncontracted collagen gel populated with allogeneic fibroblasts and covered with autologous cultured keratinocytes were used for grafting venous leg ulcers. The results were compared in the same patient with those obtained with a routinely used standard method of grafting with autologous full-thickness punch grafts. The skin equivalents and the punch grafts were grafted successfully in four of five patients. The median healing time of ulcers grafted with skin equivalents was 18 days whereas that of ulcers covered with punch grafts was 15 days. The cosmetic appearance of the skin equivalent-grafted ulcers was better than that of the punch-grafted ulcer

FREQUENT HOMOLOGOUS RECOMBINATION DEFICIENCY IN HIGH-GRADE ENDOMETRIAL CANCER PROVIDES OPPORTUNITIES FOR NOVEL THERAPEUTIC STRATEGIES

Cervix cance

FREQUENT HOMOLOGOUS RECOMBINATION DEFICIENCY IN HIGH-GRADE ENDOMETRIAL CANCER PROVIDES OPPORTUNITIES FOR NOVEL THERAPEUTIC STRATEGIES

Cervix cance